Business in the Burbs

Regeneron, Bayer announce positive test results

August

Eastview-based Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said tests of a treatment for a condition that leads to blindness showed patients made â€œhighly significant improvementsâ€ after 52 weeks.

The companies said the patients testing the treatment, called the Vascular Endothelial Growth Factor Trap-Eye, showed improvements in vision.

The treatment, which Regeneron and Bayer are seeking to commercialize, is for a condition known as wet age-related macular degeneration.

This entry was posted on Tuesday, August 19th, 2008 at 9:04 am by Allan Drury. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Biopharmaceutical

Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.